Immunitybio
IBRX · NASDAQ
$8.77+$0.35 (+4.16%)TodayMarket closed ·
Prev close $8.42
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 35.1% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.06
- Revenue estimate
- $59.53M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0918 | -$0.22 | −139.7% |
| Q1 FY26 | -$0.0714 | -$0.08 | −12.0% |
| Q4 FY25 | -$0.0959 | -$0.06 | +37.4% |
| Q3 FY25 | -$0.1102 | -$0.07 | +36.5% |
| Q2 FY25 | -$0.1122 | -$0.10 | +10.9% |
| Q1 FY25 | -$0.1306 | -$0.15 | −14.9% |
| Q4 FY24 | -$0.204 | -$0.09 | +55.9% |
| Q3 FY24 | -$0.1836 | -$0.12 | +34.6% |
Earnings calls
- 2025 Earnings Call
- 44th Annual J.P. Morgan Healthcare Conference
- Analyst/Investor Day - ImmunityBio, Inc.
- Special Call - ImmunityBio, Inc.
- Special Call - ImmunityBio, Inc.
- ImmunityBio, Inc., NantKwest, Inc. - M&A Call
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.